Rosiglitazone ameliorates acute hepatic injury via activating the Nrf2 signaling pathway and inhibiting activation of the NLRP3 inflammasome

Acute hepatic injury is a common liver disease in clinical practice. Drugs with antioxidant activity exhibit a great potential for alleviating liver injury. The present study aimed to explore the role of rosiglitazone (RSG), a previously reported compound with anti-inflammatory properties, in hepati...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Ling, Ma, Ying, Ma, Bin-Xi, Ma, Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8931635/
https://www.ncbi.nlm.nih.gov/pubmed/35340872
http://dx.doi.org/10.3892/etm.2022.11229

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8931635/
https://www.ncbi.nlm.nih.gov/pubmed/35340872
http://dx.doi.org/10.3892/etm.2022.11229

Ejemplares similares